Article
Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Annals of surgical oncology - 1 Oct 2015
Kapoor Nimmi S, Curcio Lisa D, Blakemore Carlee A, Bremner Amy K, McFarland Rachel E, West John G, Banks Kimberly C
Abstract excerpt
BACKGROUND: Recently introduced multigene panel testing including BRCA1 and BRCA2 genes for hereditary cancer risk has raised concerns with the ability to detect all deleterious BRCA1/2 mutations compared to older methods of sequentially testing BRCA1/2 separately. The purpose of this study was to evaluate rates of pathogenic BRCA1/2 mutations and variants of uncertain significance (VUS) between previous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.